Peter Ellis, Chairman of Motilent says: "FDA clearance is an important step for Motilent as we move to the US market. Through our partnership with Nuance, and via our own direct sales capabilities, we will have extensive market access, ensuring more US patients have access to Motilent’s technology. This is an incredibly exciting milestone for us on our mission to get every patient with digestive disease on the right treatment, at the right time."
To mark their launch in the US, Motilent will be exhibiting for the first time at RSNA 2021, the Radiological Society of North America’s annual conference, taking place 28th November-1st December 2021. The team will showcase their technologies (booth 5158) and discuss GIQuant in real world settings, including initial experiences and findings from a year's use at Frimley Park Hospital NHS Foundation Trust.
Ad Statistics
Times Displayed: 22281
Times Visited: 445 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
Motilent will be exhibiting at RSNA 2021 (28th November-1st December), at booth 5158.
About Motilent
Motilent is a technology startup on a mission to change the way we see the gut. Specialising in the assessment of digestive diseases using medical image analysis, their main focus areas include Crohn’s Disease, Irritable Bowel Syndrome (IBS) and Gastroparesis. Motilent’s first product GIQuant aims to help clinicians to identify earlier when patients stop responding to immunotherapy.
Back to HCB News
